Zai Lab Ltd. ADR (ZLAB) News
Filter ZLAB News Items
ZLAB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ZLAB News Highlights
- ZLAB's 30 day story count now stands at 6.
- Over the past 20 days, the trend for ZLAB's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- LAB, DRUG and CDE are the most mentioned tickers in articles about ZLAB.
Latest ZLAB News From Around the Web
Below are the latest news stories about ZAI LAB LTD that investors may wish to consider to help them evaluate ZLAB as an investment opportunity.
Betting Big: 3 Tech Stocks Primed for a BreakoutUnlock hidden growth opportunities in the innovation space by exploring our curated list of tech stocks to buy now for big upside potential. |
Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in ChinaSHANGHAI, China and CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation for efgartigimod alfa injection (subcutaneous injection) (efgartigimod SC) for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). The Breakthrough Therapy Designation for efgartigimod SC was s |
Why Shares of Zai Lab Limited Were Jumping on TuesdayShares of Zai Lab (NASDAQ: ZLAB) were up more than 10% as of 11 a.m. on Tuesday. The Chinese biotech stock rose after the company announced positive phase 3 trial data regarding Tivdak as a front-line therapy to treat metastatic cervical cancer in patients who have had no more than two prior systemic regimens. Seagen (NASDAQ: SGEN) and Genmab (NASDAQ: GMAB) are collaborating with Zai Lab on the development of Tivdak. |
Seagen's (SGEN) Late-Stage Cervical Cancer Study Meets GoalsSeagen (SGEN) and Genmab announce that the late-stage study of Tivdak in the second-line treatment of adult patients with recurrent or metastatic cervical cancer meets the primary and secondary goals. |
Zai Lab (ZLAB) Up on Breakthrough Therapy Tag for Oncology DrugZai Lab (ZLAB) gains on receiving Breakthrough Therapy designation for repotrectinib from the Center for Drug Evaluation of the National Medical Products Administration in China. |
Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in ChinaCandidate precision medicine has shown encouraging clinical activity for both ROS1-positive NSCLC and NTRK fusion-positive advanced solid tumorsSHANGHAI, China and CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation for investigational repotrectinib for the treatment of patients with advanced solid tum |
Zai Lab Announces Participation in September Investor ConferencesSHANGHAI, China and CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the company’s senior management team will participate in the following investor conferences in September 2023: Citi's 18th Annual BioPharma ConferencePanel Discussion: Wednesday, September 6th at 10:30 a.m. ETLocation: Boston 2023 Cantor Global Healthcare ConferenceFireside Chat: Wednesday, September 27th at 8:00 a.m. ETLocation: New York About Zai La |
Penn downgraded, Roblox upgraded: Wall Street's top analyst callsPenn downgraded, Roblox upgraded: Wall Street's top analyst calls |
Zai Lab Announces Second Quarter 2023 Financial Results and Corporate UpdatesTotal product revenue of $68.9 million for the second quarter of 2023, representing 45% y-o-y growth; 53% y-o-y growth at constant exchange rateVYVGART® (efgartigimod alfa injection) approved in China as first-and-only neonatal Fc receptor (FcRn) blocker for generalized myasthenia gravis (gMG); preparations for launch underway; subcutaneous efgartigimod for gMG under Biologics License Application (BLA) reviewPrimary endpoint met in ADHERE trial of VYVGART Hytrulo (efgartigimod alfa and hyaluroni |
12 Stocks with Biggest Upside Potential According to AnalystsIn this article, we will take a look at the 12 stocks with biggest upside potential according to analysts. To skip our analysis of recent market trends, you can go directly to 5 Stocks with Biggest Upside Potential. The stock market has been in constant turmoil during the last few years. The markets were severely […] |